"The Americans have need of the telephone, but we do not. We have plenty of messenger boys."
|Application No.||Application Title||Issue Date|
|20140051702||Use of Aminoindane Compounds in Treating Overactive Bladder and Interstitial Cystitis|
The present application provides methods of using the aminoindane compounds of formula (I) or (II) in treating an overactive bladder or interstitial cystitis by administering one or more of the compounds to a patient.
|20140051673||AMPK-Activating Heterocycloalkyloxy(Hetero)Aryl Carboxamide, Sulfonamide And Amine Compounds And Methods For Using The Same|
Disclosed are carboxamide, sulfonamide and amine compounds, as well as pharmaceutical compositions and methods of use. One embodiment is a compound having the structure
in which R1, R2, ...
|20140038948||COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR|
Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases....
|20140038963||Multifunctional Radical Quenchers For The Treatment Of Mitochondrial Dysfunction|
The present disclosure provides methods for identifying therapeutic agents that are multifunctional radical quenchers. It also provides compounds of formula (I), (II), or (II-A): and pharmaceutically acceptable salts thereof, compositions comprising these compounds, and...
|20140030223||INHIBITORS OF FLAVIVIRIDAE VIRUSES|
Provided are compounds of Formula I:
and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, ...
|20140024645||PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS|
Phenoxy acetic acids and phenyl propionic acids and their use in treating type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, or obesity are provided herein. The present compounds are activators of PPARδ and may be useful for treating con...
|20140024647||AROMATIC HETEROCYCLIC DERIVATIVE HAVING TRPV4-INHIBITING ACTIVITY|
A compound having TRPV4 inhibitory activity or a pharmaceutically acceptable salt thereof is provided. The present invention is related to a compound represented by the formula (I), wherein R1a is substituted or unsubstituted alkyl or the like; R1b
|20140023611||COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT|
Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions compr...
|20140011807||NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND|
The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I]:
wherein R1 is a cycloalkyl group and the like, R22 is an optionally substituted a...
|20140011796||PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER|
The present invention provides MDM2 inhibitor compounds of Formula I,
|20140005178||AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS|
The present disclosure relates to new azabiphenylaminobenzoic acid derivatives of formula (I); as well as processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy as inhibitors of the dehydroorotate dihydrogenase (DHODH)....
|20130336920||COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT|
Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I):
|20130338168||Combinations of JAK Inhibitors|
The invention provides a pharmaceutical combination comprising:
|20130331391||VIRAL POLYMERASE INHIBITORS|
Compounds of formula I:
wherein X, R2, R3, R3a, R3b, R5 and R6 are defined herein, are useful as inhibitors of the hepatitis C virus NS5B poly...
The present invention provides a compound of formula (I):
and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided are pharmac...
|20130324501||DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS|
Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols according to formula (I) are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme....
There are provided compounds of the formula
wherein X, Y, Z, R1, R2 and R3 are as described herein
|20130317027||COMPOUNDS AND THERAPEUTIC USES THEREOF|
The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, ischemia, and other complications associated with these...
Compounds are provided that are modulators of the C5a receptor. The compounds are substituted piperidines and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of C5a receptors....
|20130310378||4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS|
The present invention relates to novel 4-(4-pyridyl)-benzamides of the formula (I). The compounds I possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of Rho kinases (ROCKs). R1 and R...
|20130310377||NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL|
Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung...
|20130310379||MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF|
Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein....
|20130303507||SUBSTITUTED HETERO-BIARYL COMPOUNDS AND THEIR USES|
The present invention provides a compound of formula (II):
|20130303539||COMPOUNDS WITH TRPV4 ACTIVITY, COMPOSITIONS AND ASSOCIATED METHODS THEREOF|
Compounds, compositions and methods useful for treating ocular diseases are provided. In particular, antagonists of TRPV4, their synthesis, pharmaceutical compositions thereof and methods of treating ocular diseases such as glaucoma, are disclosed....
|20130296274||PYRROLIDINONES AS METAP-2 INHIBITORS|
Compounds of the formula I in which R1, R2, R3 and R4 have the meanings indicated in Claim 1, are inhibitors of methionine aminopeptidase and can be employed for the treatment of tumours....
|20130281452||SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS|
Substituted 4-aminobenzamides, pharmaceutical compositions containing these compounds and also methods of using these compounds in the treatment and/or prophylaxis of pain and further diseases and/or disorders....
|20130281453||ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES|
Serine hydrolases are implicated in malconditions such as cancer, central nervous system disorders, cardiovascular disorders, obesity, and metabolic disorders. Many serine hydrolases expressed in proteomic libraries are of unknown function in vivo. Compounds identified ...
Novel compounds or salts thereof, or crystals thereof, which inhibit Axl and are useful for treating diseases caused by Axl hyperfunction, diseases associated with Axl hyperfunction and/or diseases accompanied by Axl hyperfunction are provided. Pyridone derivatives repr...
|20130281387||Chemosensory Receptor Ligand-Based Therapies|
Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein...
|20130281443||INHIBITORS OF FOCAL ADHESION KINASE|
The invention provides inhibitors of focal adhesion kinase, an enzyme involved in the attachment of the cytoskeleton of a cell to an extracellular matrix, which has been implicated in processes such as cell migration, cell proliferation, and cell survival. The inhibitor...
|20130281449||Oxazine Derivatives and their Use in the Treatment of Neurological Disorders|
The invention relates to novel heterocyclic compounds of the formula (I), in which all of the variables are as defined in the specification, in free form or in pharmaceutically acceptable salt form, to their preparation, to their medical use and to medicaments comprisin...
|20130273034||NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT|
The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An illustrative compound of the invention is shown below:
|20130273004||SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE|
Selected heterocyclic compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions...
|20130267516||SUBSTITUTED CYCLOPENTYL-AZINES AS CASR-ACTIVE COMPOUNDS|
Compounds of general formula I, (formula [I)], their use as calcium receptor-active compounds for the prophylaxis, treatment or amelioration of physiological disorders or diseases associated with disturbances of CaSR activity, such as hyperparathyroidism, pharmaceutical...
Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in ...
|20130252957||PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS|
The present invention provides compounds that are alpha4 integrin antagonists having a structure according to the following formula:
or a tautomer, mixture of tautomers, salt or solvate thereof, wherein Cy, r...
There are provided compounds of the formula
wherein X, Y, Z, R1, R2, R3 and R4 are as described herein
The present invention provides novel phenicol derivatives, their use for the treatment of infections in mammals, pharmaceutical composition containing these novel compounds, and methods for the preparation of these compounds....
|20130237539||Compounds and Compositions for Treating Cancer|
The invention relates to compounds and composition for the treatment and prevention of cancer. The invention also covers all diseases that may be treated by selective modulation of levels of reactive oxygen species in diseased cells versus normal cells. Methods for the ...
|20130237525||LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS|
The present invention relates to lactam derivatives of formula (I)
wherein Y, R1, R2 and R3 are as described in the description, to their preparation, to pharmaceutically acce...